Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

2200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2018-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy and safety of Naoxintong Capsule in the secondary prevention of ischemic stroke by the multi-center, randomized,double-blind，placebo-controlled trial design project.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

NCT04150835

Acute Ischemic Stroke Stroke, Acute Stroke, Ischemic

UNKNOWN PHASE4

Trial of pRehospital Intervention With trAditional Chinese Medicine for Acute strokE

NCT04275349

Stroke Acute Ischemic Stroke Acute Intracranial Hemorrhage

UNKNOWN

Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke

NCT04415164

Acute Ischemic Stroke

UNKNOWN PHASE4

Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke

NCT01762163

Ischemic Stroke

COMPLETED PHASE4

Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

NCT05559307

Ischemic Stroke, Acute

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The research employs a random, double-blind, multicenter, placebo parallel and controlled design to observe the clinical effect of Naoxintong capsule in the treatment in ischemic stroke of the blood stasis syndrome on the secondary prevention，which is funded by Science and Technology Commission of Shanghai Municipality.The therapeutic drug of the research is Naoxintong capsule on the market for treatment and prevention of stroke, applicable to stroke patients caused by qi deficiency, blood stasis and venation stasis.The research will be carried out in 24 hospitals.It is a total number of 2200 volunteers，who will meet the inclusion criteria other than the exclusion criteria and agree to participate in the research.Volunteers will be randomly assigned to the experimental group or the control group. The trial drug for the experimental group is Naoxintong capsule, while that for the control group is a kind of placebo capsule.Volunteers will be regularly followed up during the experimental period of 2 years. It will be to evaluate the clinical efficacy of Naoxintong capsule on the secondary prevention by the stroke recurrence and mortality.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time

Group Type EXPERIMENTAL

Naoxintong Capsule

Intervention Type DRUG

This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.

Control group

On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type DRUG

placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Naoxintong Capsule

This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.

Intervention Type DRUG

Placebo

placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chinese Herbal Compound Placebo of Chinese Herbal Compound

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult volunteers aged ≤ 90 years old, ≥18 years old；
* Conforming to the diagnostic criteria of cerebral infarction under the 2010 version of Chinese Guidelines for Treatment of Acute Ischemic Stroke；
* Conforming to diagnostic criteria of the stasis type of TCM on the ischemic stroke；
* The onset of acute cerebral infarction ≥ 10 days；
* Consciousness awake；
* Volunteers agree to accept the program and sign informed consent.

Exclusion Criteria

* Excluding the patients of the yin deficiency type of ischemic stroke.The diagnostic criteria of Yin deficiency type of ischemic stroke is that sudden onset of disease；being signs or symptoms of of neurological deficit；CT or MRI examination showing intracranial ischemic lesions；Scarlet tongue；
* The volunteers with severe heart diseases, cardiac insufficiency, hepatosis, renal insufficiency, respiratory failure, malignant tumour, alimentary tract hemorrhage, etc. who may fail to complete the two-year follow-up；
* Psychiatric patients；
* Pregnants and lactating women；
* Volunteers in other clinical trials；
* Volunteers who are not suitable for this clinical trial according to the researchers for other reasons.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiaofei Yu

Shuguang Hospital

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiao F Yu, Doctor

Role: STUDY_CHAIR

ShuGuang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.